The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지
DOI QR코드

DOI QR Code

Characterization of hypotensive and vasorelaxant effects of PHAR-DBH-Me a new cannabinoid receptor agonist

  • Received : 2021.05.11
  • Accepted : 2021.12.04
  • Published : 2022.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

The effect of PHAR-DBH-Me, a cannabinoid receptor agonist, on different cardiovascular responses in adult male rats was analyzed. The blood pressure was measured directly and indirectly. The coronary flow was measured by Langendorff preparation, and vasomotor responses induced by PHAR-DBH-Me in aortic rings precontracted with phenylephrine (PHEN) were analyzed. The intravenous injection of the compound PHAR-DBH-Me (0.018-185 ㎍/kg) resulted in decreased blood pressure; maximum effect was observed at the dose of 1,850 ㎍/kg. A concentrationdependent increase in the coronary flow was observed in a Langendorff preparation. In the aortic rings, with and without endothelium, pre-contracted with PHEN (10-6 M), the addition of PHAR-DBH-Me to the superfusion solution (10-12-10-5 M), produced a vasodilator response, which depends on the concentration and presence of the endothelium. L-NAME inhibited these effects. Addition of CB1 receptor antagonist (AM 251) did not modify the response, while CB2 receptor antagonist (AM630) decreased the potency of relaxation elicited by PHAR-DBH-Me. Indomethacin shifted the curve concentration-response to the left and produced an increase in the magnitude of the maximum endothelium dependent response to this compound. The maximum effect of PHAR-DBH-Me was observed with the concentration of 10-5 M. These results show that PHAR-DBH-Me has a concentration-dependent and endothelium-dependent vasodilator effect through CB2 receptor. This vasodilation is probably mediated by the synthesis/release of NO. On the other hand, it is suggested that PHAR-DBH-Me also induces the release of a vasoconstrictor prostanoid.

Keywords

Acknowledgement

Authors thank to Miss Maria Teresa Espinosa Garcia for its skillful technical assistance.

References

  1. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946-1949. https://doi.org/10.1126/science.1470919
  2. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995;215:89-97. https://doi.org/10.1006/bbrc.1995.2437
  3. Cravatt BF, Prospero-Garcia O, Siuzdak G, Gilula NB, Henriksen SJ, Boger DL, Lerner RA. Chemical characterization of a family of brain lipids that induce sleep. Science. 1995;268:1506-1509. https://doi.org/10.1126/science.7770779
  4. Pertwee RG. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem. 2010;17:1360-1381. https://doi.org/10.2174/092986710790980050
  5. Steffens S, Pacher P. Targeting cannabinoid receptor CB2 in cardiovascular disorders: promises and controversies. Br J Pharmacol. 2012;167:313-323. https://doi.org/10.1111/j.1476-5381.2012.02042.x
  6. Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19:833. https://doi.org/10.3390/ijms19030833
  7. Hiley CR. Endocannabinoids and the heart. J Cardiovasc Pharmacol. 2009;53:267-276. https://doi.org/10.1097/FJC.0b013e318192671d
  8. Aghazadeh Tabrizi M, Baraldi PG, Borea PA, Varani K. Medicinal chemistry, pharmacology, and potential therapeutic benefits of cannabinoid CB2 receptor agonists. Chem Rev. 2016;116:519-560. https://doi.org/10.1021/acs.chemrev.5b00411
  9. Rom S, Zuluaga-Ramirez V, Dykstra H, Reichenbach NL, Pacher P, Persidsky Y. Selective activation of cannabinoid receptor 2 in leukocytes suppresses their engagement of the brain endothelium and protects the blood-brain barrier. Am J Pathol. 2013;183:1548-1558. https://doi.org/10.1016/j.ajpath.2013.07.033
  10. Page RL 2nd, Allen LA, Kloner RA, Carriker CR, Martel C, Morris AA, Piano MR, Rana JS, Saucedo JF; American Heart Association Clinical Pharmacology Committee and Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Lifestyle and Cardiometabolic Health; Council on Quality of Care and Outcomes Research. Medical marijuana, recreational cannabis, and cardiovascular health: a scientific statement from the American Heart Association. Circulation. 2020;142:e131-e152.
  11. Lopez-Ortiz M, Herrera-Solis A, Luviano-Jardon A, Reyes-Prieto N, Castillo I, Monsalvo I, Demare P, Mendez-Diaz M, Regla I, Prospero-Garcia O. Chemoenzymatic synthesis and cannabinoid activity of a new diazabicyclic amide of phenylacetylricinoleic acid. Bioorg Med Chem Lett. 2010;20:3231-3234. https://doi.org/10.1016/j.bmcl.2010.04.074
  12. Vidrio H, Medina M, Gonzalez-Romo P, Lorenzana-Jimenez M, Diaz-Arista P, Baeza A. Semicarbazide-sensitive amine oxidase substrates potentiate hydralazine hypotension: possible role of hydrogen peroxide. J Pharmacol Exp Ther. 2003;307:497-504. https://doi.org/10.1124/jpet.103.055350
  13. Maggi CA, Meli A. Suitability of urethane anesthesia for physiopharmacological investigations in various systems. Part 2: cardiovascular system. Experientia. 1986;42:292-297. https://doi.org/10.1007/BF01942510
  14. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376. https://doi.org/10.1038/288373a0
  15. Sudhahar V, Shaw S, Imig JD. Mechanisms involved in oleamideinduced vasorelaxation in rat mesenteric resistance arteries. Eur J Pharmacol. 2009;607:143-150. https://doi.org/10.1016/j.ejphar.2009.02.002
  16. Quinonez-Bastidas GN, Palomino-Hernandez O, Lopez-Ortiz M, Rocha-Gonzalez HI, Gonzalez-Anduaga GM, Regla I, Navarrete A. Antiallodynic effect of PhAR-DBH-Me involves cannabinoid and TRPV1 receptors. Pharmacol Res Perspect. 2020;8:e00663.
  17. Ligresti A, De Petrocellis L, Di Marzo V. From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. Physiol Rev. 2016;96:1593-1659. https://doi.org/10.1152/physrev.00002.2016
  18. Pertwee RG. Endocannabinoids and their pharmacological actions. Handb Exp Pharmacol. 2015;231:1-37. https://doi.org/10.1007/978-3-319-20825-1_1
  19. Hebert-Chatelain E, Desprez T, Serrat R, Bellocchio L, Soria-Gomez E, Busquets-Garcia A, Pagano Zottola AC, Delamarre A, Cannich A, Vincent P, Varilh M, Robin LM, Terral G, Garcia-Fernandez MD, Colavita M, Mazier W, Drago F, Puente N, Reguero L, Elezgarai I, et al. A cannabinoid link between mitochondria and memory. Nature. 2016;539:555-559. https://doi.org/10.1038/nature20127
  20. Mendizabal-Zubiaga J, Melser S, Benard G, Ramos A, Reguero L, Arrabal S, Elezgarai I, Gerrikagoitia I, Suarez J, Rodriguez De Fonseca F, Puente N, Marsicano G, Grandes P. Cannabinoid CB1 receptors are localized in striated muscle mitochondria and regulate mitochondrial respiration. Front Physiol. 2016;7:476.
  21. Bonz A, Laser M, Kullmer S, Kniesch S, Babin-Ebell J, Popp V, Ertl G, Wagner JA. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol. 2003;41:657-664. https://doi.org/10.1097/00005344-200304000-00020
  22. Chen XP, Yang W, Fan Y, Luo JS, Hong K, Wang Z, Yan JF, Chen X, Lu JX, Benovic JL, Zhou NM. Structural determinants in the second intracellular loop of the human cannabinoid CB1 receptor mediate selective coupling to GS and Gi. Br J Pharmacol. 2010;161:1817-1834. https://doi.org/10.1111/j.1476-5381.2010.01006.x
  23. Zheng C, Chen L, Chen X, He X, Yang J, Shi Y, Zhou N. The second intracellular loop of the human cannabinoid CB2 receptor governs G protein coupling in coordination with the carboxyl terminal domain. PLoS One. 2013;8:e63262. https://doi.org/10.1371/journal.pone.0063262
  24. Lozovaya N, Min R, Tsintsadze V, Burnashev N. Dual modulation of CNS voltage-gated calcium channels by cannabinoids: focus on CB1 receptor-independent effects. Cell Calcium. 2009;46:154-162. https://doi.org/10.1016/j.ceca.2009.07.007
  25. Wheal AJ, Bennett T, Randall MD, Gardiner SM. Cardiovascular effects of cannabinoids in conscious spontaneously hypertensive rats. Br J Pharmacol. 2007;152:717-724. https://doi.org/10.1038/sj.bjp.0707410
  26. Ho WS, Gardiner SM. Acute hypertension reveals depressor and vasodilator effects of cannabinoids in conscious rats. Br J Pharmacol. 2009;156:94-104. https://doi.org/10.1111/j.1476-5381.2008.00034.x
  27. Lepicier P, Bouchard JF, Lagneux C, Lamontagne D. Endocannabinoids protect the rat isolated heart against ischaemia. Br J Pharmacol. 2003;139:805-815. https://doi.org/10.1038/sj.bjp.0705313
  28. Underdown NJ, Hiley CR, Ford WR. Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. Br J Pharmacol. 2005;146:809-816. https://doi.org/10.1038/sj.bjp.0706391
  29. Al Kury LT, Voitychuk OI, Yang KH, Thayyullathil FT, Doroshenko P, Ramez AM, Shuba YM, Galadari S, Howarth FC, Oz M. Effects of the endogenous cannabinoid anandamide on voltage-dependent sodium and calcium channels in rat ventricular myocytes. Br J Pharmacol. 2014;171:3485-3498. https://doi.org/10.1111/bph.12734
  30. Hoi PM, Hiley CR. Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor. Br J Pharmacol. 2006;147:560-568. https://doi.org/10.1038/sj.bjp.0706643
  31. Kozlowska H, Baranowska M, Schlicker E, Kozlowski M, Laudanski J, Malinowska B. Identification of the vasodilatory endothelial cannabinoid receptor in the human pulmonary artery. J Hypertens. 2007;25:2240-2248. https://doi.org/10.1097/HJH.0b013e3282ef7a0a
  32. Lepicier P, Lagneux C, Sirois MG, Lamontagne D. Endothelial CB1-receptors limit infarct size through NO formation in rat isolated hearts. Life Sci. 2007;81:1373-1380. https://doi.org/10.1016/j.lfs.2007.08.042
  33. Silva BR, Pernomian L, De Paula TD, Grando MD, Bendhack LM. Endothelial nitric oxide synthase and cyclooxygenase are activated by hydrogen peroxide in renal hypertensive rat aorta. Eur J Pharmacol. 2017;814:87-94. https://doi.org/10.1016/j.ejphar.2017.07.047
  34. Herradon E, Martin MI, Lopez-Miranda V. Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. Br J Pharmacol. 2007;152:699-708. https://doi.org/10.1038/sj.bjp.0707404
  35. Romano MR, Lograno MD. Cannabinoid agonists induce relaxation in the bovine ophthalmic artery: evidences for CB1 receptors, nitric oxide and potassium channels. Br J Pharmacol. 2006;147:917-925. https://doi.org/10.1038/sj.bjp.0706687
  36. Hoyer FF, Steinmetz M, Zimmer S, Becker A, Lutjohann D, Buchalla R, Zimmer A, Nickenig G. Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. J Mol Cell Cardiol. 2011;51:1007-1014. https://doi.org/10.1016/j.yjmcc.2011.08.008
  37. Gonzalez C, Herradon E, Abalo R, Vera G, Perez-Nievas BG, Leza JC, Martin MI, Lopez-Miranda V. Cannabinoid/agonist WIN 55,212-2 reduces cardiac ischaemia-reperfusion injury in Zucker diabetic fatty rats: role of CB2 receptors and iNOS/eNOS. Diabetes Metab Res Rev. 2011;27:331-340. https://doi.org/10.1002/dmrr.1176
  38. Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley NE, Mezey E, Razdan RK, Zimmer A, Kunos G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A. 1999;96:14136-14141. https://doi.org/10.1073/pnas.96.24.14136
  39. Chen G, Suzuki H, Weston AH. Acetylcholine releases endothelium- derived hyperpolarizing factor and EDRF from rat blood vessels. Br J Pharmacol. 1988;95:1165-1174. https://doi.org/10.1111/j.1476-5381.1988.tb11752.x
  40. Hecker M, Bara AT, Bauersachs J, Busse R. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J Physiol. 1994;481(Pt 2):407-414. https://doi.org/10.1113/jphysiol.1994.sp020449
  41. Wheal AJ, Alexander SP, Randall MD. Vasorelaxation to Noleoylethanolamine in rat isolated arteries: mechanisms of action and modulation via cyclooxygenase activity. Br J Pharmacol. 2010;160:701-711. https://doi.org/10.1111/j.1476-5381.2010.00770.x